These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme. Soni M; Kiff C; Carroll R; Stein D; Saragoussi D; Nassar A; Maisey N; Tyas D Future Oncol; 2021 Aug; 17(24):3163-3174. PubMed ID: 34098737 [TBL] [Abstract][Full Text] [Related]
12. Nivolumab-associated acute glomerulonephritis: a case report and literature review. Jung K; Zeng X; Bilusic M BMC Nephrol; 2016 Nov; 17(1):188. PubMed ID: 27876011 [TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature. Yahata M; Nakaya I; Sakuma T; Sato H; Aoki S; Soma J BMC Res Notes; 2013 Nov; 6():450. PubMed ID: 24207130 [TBL] [Abstract][Full Text] [Related]
14. Nivolumab exerts therapeutic effects against metastatic lesions from early gastric adenocarcinoma with a small proportion of neuroendocrine carcinoma after gastrectomy: a case report. Sawayama H; Komohara Y; Hirao H; Sakata K; Takata N; Yoshinaka I; Harada K; Baba H Clin J Gastroenterol; 2020 Oct; 13(5):759-765. PubMed ID: 32592148 [TBL] [Abstract][Full Text] [Related]
15. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948 [TBL] [Abstract][Full Text] [Related]
16. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217). Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035 [TBL] [Abstract][Full Text] [Related]
17. A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy. Satoyoshi R; Muto O; Masuda A; Kotanagi K; Kichiraku T; Kudoh K; Sawada T; Miyazawa H; Kotanagi H Clin J Gastroenterol; 2019 Feb; 12(1):15-19. PubMed ID: 30206777 [TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. Tokumo K; Masuda T; Miyama T; Miura S; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Yoshida T; Iwamoto H; Fujitaka K; Hamada H; Hattori N Lung Cancer; 2018 May; 119():21-24. PubMed ID: 29656748 [TBL] [Abstract][Full Text] [Related]
20. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. Horisberger A; La Rosa S; Zurcher JP; Zimmermann S; Spertini F; Coukos G; Obeid M J Immunother Cancer; 2018 Dec; 6(1):156. PubMed ID: 30587227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]